Literature DB >> 30058598

Immunotherapy for esophageal squamous cell carcinoma: a review.

Kosaku Mimura1,2,3, Leo Yamada1, Daisuke Ujiie1, Suguru Hayase1, Takeshi Tada1, Hiroyuki Hanayama1, Aung Kyi Thar Min1, Masahiko Shibata1,2, Tomoyuki Momma1, Zenichiro Saze1, Shinji Ohki1, Koji Kono1.   

Abstract

Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.

Entities:  

Keywords:  cancer vaccine; esophageal squamous cell carcinoma; immune checkpoint inhibitors; immunotherapy

Mesh：

Substances：

Year:  2018        PMID： 30058598      PMCID： PMC6141453          DOI： 10.5387/fms.2018-09

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN： 0016-2590


  47 in total

Review 1.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

2.  [Therapeutic Cancer Vaccine and Immune Checkpoint Inhibitor].

Authors:  Kousaku Mimura; Koji Kono
Journal:  Gan To Kagaku Ryoho       Date:  2017-09

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Yoshiyuki Suzuki; Kousaku Mimura; Yuya Yoshimoto; Mitsuaki Watanabe; Yu Ohkubo; Shinichirou Izawa; Kazutoshi Murata; Hideki Fujii; Takashi Nakano; Koji Kono
Journal:  Cancer Res       Date:  2012-06-14       Impact factor: 12.701

5.  High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

Authors:  Takuro Saito; Hisashi Wada; Makoto Yamasaki; Hiroshi Miyata; Hiroyoshi Nishikawa; Eiichi Sato; Shinichi Kageyama; Hiroshi Shiku; Masaki Mori; Yuichiro Doki
Journal:  Vaccine       Date:  2014-09-13       Impact factor: 3.641

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

10.  Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.

Authors:  Kaiyan Chen; Guoping Cheng; Fanrong Zhang; Nan Zhang; Dan Li; Jiaoyue Jin; Junzhou Wu; Lisha Ying; Weimin Mao; Dan Su
Journal:  Oncotarget       Date:  2016-05-24
View more
  12 in total

1.  Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.

Authors:  Dongyang Yang; Fei Xu; Xiaorong Lai; Ying Li; Huibing Gao; Ying Xu; Rongrong Chen; Dong Ma
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma.

Authors:  Wu Lin; Jiong Qian; Haohao Wang; Ling Ren; Yan Yang; Chuanzhi Chen; Xiangliu Chen; Yingying Huang; Jin Liu; Nong Xu; Lisong Teng
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

3.  The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer.

Authors:  Xiaoling Xu; Ding Wang; Na Li; Jiamin Sheng; Mingying Xie; Zichao Zhou; Guoping Cheng; Yun Fan
Journal:  Ann Surg Oncol       Date:  2021-11-09       Impact factor: 4.339

Review 4.  Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.

Authors:  Yoshihiro Kakeji; Taro Oshikiri; Gosuke Takiguchi; Shingo Kanaji; Takeru Matsuda; Tetsu Nakamura; Satoshi Suzuki
Journal:  Esophagus       Date:  2020-09-22       Impact factor: 4.230

Review 5.  A good start of immunotherapy in esophageal cancer.

Authors:  Qian Zhao; Jinming Yu; Xue Meng
Journal:  Cancer Med       Date:  2019-06-23       Impact factor: 4.452

6.  Comprehensive Analysis of Competitive Endogenous RNAs Network, Being Associated With Esophageal Squamous Cell Carcinoma and Its Emerging Role in Head and Neck Squamous Cell Carcinoma.

Authors:  Donghu Yu; Xiaolan Ruan; Jingyu Huang; Weidong Hu; Chen Chen; Yu Xu; Jinxuan Hou; Sheng Li
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

7.  Novel mechanism of immune evasion mediated by tumor-associated macrophages in esophageal squamous cell carcinoma.

Authors:  Fei-Yu Diao
Journal:  Thorac Cancer       Date:  2020-07-19       Impact factor: 3.500

8.  An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma.

Authors:  Hongpan Zhang; Qi Shi; Zhihao Yang; Kaige Wang; Zhiyu Zhang; Zheng Huang; Xiaobin Cui; Feng Li
Journal:  Front Mol Biosci       Date:  2021-03-18

9.  Role of Integrin β1 in the progression and chemo-resistance of esophageal squamous cell carcinoma.

Authors:  Ying-Hua Xie; Li-Qiang Ran; Zhi-Yong Wu; Chun Sun; Xiu-E Xu; Hai-Ying Zou; Wang-Kai Fang; Jian-Jun Xie
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

10.  AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.

Authors:  Yuxuan Zhu; Ting Yuan; Yuan Zhang; Jianyou Shi; Lan Bai; Xingmei Duan; Rongsheng Tong; Lei Zhong
Journal:  Drug Des Devel Ther       Date:  2019-12-19       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.